title: Pilot study of preoperative combined modality treatment for locally advanced operable oesophageal carcinoma: toxicities and long-term outcome.
abstract: OBJECTIVE
  Paclitaxel, a radiosensitiser, has significant activity in oesophageal cancer. We aimed to conduct a feasibility study of preoperative chemoradiation using paclitaxel, cisplatin and 5-fluorouracil (5-FU).
  
  
  METHODS
  Sixteen eligible patients were enrolled. Infusional 5-FU, paclitaxel and cisplatin were given for 6 weeks before and concurrent with radiation. Conformal radiotherapy was delivered in two phases (45 Gy in 25 fractions).
  
  
  RESULTS
  A total of 62.5% of the patients experienced Grade 3-4 toxicities, 50% required admission; one patient died during the neo-adjuvant phase. Twelve (75%) patients had oesophagectomy, and two (12.5%) died after surgery. Pathological complete remission (PCR) and minimal residual disease were observed in 25% (95% CI 0.5-49.5%) and 18% (95% CI 0-38%) of patients, respectively, who underwent surgery. The median survival was 39.7 months (95% CI 15, not reached); 1-, 2-, 3-, and 4-year survivals were 75% (95% CI 56.5-99.5), 56.3% (36.5-86.7), 50% (30.6-81.6), and 50% (30.6-81.6), respectively.
  
  
  CONCLUSIONS
  Paclitaxel, cisplatin and 5-FU (TCF)-chemoradiation is an active regimen; the current dose schedule tested is associated with unacceptable toxicity, and cannot be recommended for routine clinical use.
authors.affiliation: Velindre Hospital, Whitchurch, Cardiff, Wales, UK.
authors.forename: S
authors.initials: S
authors.lastname: Mukherjee
authors.forename: J
authors.initials: J
authors.lastname: Abraham
authors.forename: A
authors.initials: A
authors.lastname: Brewster
authors.forename: R
authors.initials: R
authors.lastname: Hardwick
authors.forename: T
authors.initials: T
authors.lastname: Havard
authors.forename: W
authors.initials: W
authors.lastname: Lewis
authors.forename: C
authors.initials: C
authors.lastname: Askill
authors.forename: J
authors.initials: J
authors.lastname: Manson
authors.forename: G T
authors.initials: GT
authors.lastname: Williamst
authors.forename: S A
authors.initials: SA
authors.lastname: Roberts
authors.forename: J
authors.initials: J
authors.lastname: Court
authors.forename: T
authors.initials: T
authors.lastname: Crosby
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011300:Preoperative Care; D011446:Prospective Studies; D020266:Radiotherapy, Conformal; D016019:Survival Analysis
chemical_list: D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil